吉西他滨联合顺铂治疗中晚期非小细胞肺癌临床近期疗效观察

目的:观察国产吉西他滨(GEM,泽菲)联合顺铂(PDD)组成的GP方案治疗中晚期非小细胞肺癌(NSCLC)的疗效及毒副作用.方法:42例经病理或细胞学证实的中晚期非小细胞肺癌患者,采用GP方案化疗,GEM 1 000 mg/m2第1天、第8天静滴,PDD 80 mg/m2第1天静滴,21 d为1个周期,使用2～4个周期.结果:42例中,完全缓解(CR)2例(4.76%),部分缓解(PR)17例(40.48%),稳定(SD)14例(33.33%),进展(PD)9例(21.42%),客观有效率(RR=CR+PR)为45.24%(19/42).毒副作用主要表现为血白细胞、血小板下降,恶心呕吐等,但均可耐受.结论:吉西他滨联合顺铂治疗中晚期非小细胞肺癌有较好的疗效,毒副作用可耐受,值得临床推广应用.

The treatment with Gemcitabine combined and Cisplatin in the intermediate-advanced stage of non-small cell lung cancer

Objective: To observe the therapeutic effect and side effect of Gemcitabine combined and Cisplatin in the intermediate-advanced stage of non-smaU cell lung cancer (NSCLC). Methods: 42 patients with advanced NSCLC enrolled in allotted to the study. The patients were treated with GP regiment, GEM 1 000 mg/m2, dl and d8 intravenous infusion. PDD 80 mg/m2 dl intravenous infusion. 21 days for one cycle,all patients received 2--4 cycles therapies. Results: In 42 cases, CR 2 eases (4.76%),PR 17 cases (40.48%),SD 14 cases (33.33%),PD 9 cases (21.42%),RR(CR+PR) was 45.24% (19/42). The main side effects were leucopeenia,thrombocytopenia,gastro-intestinal reaction. Conclusion: Gemcitabine andcisplatin in the treatment of advanced non-small cell lung cancer have better efficacy, side effects can be tolerated, it is worth clinical application.